PARIS and TARRYTOWN, N.Y., Nov. 11, 2018 /PRNewswire/ -- New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent ® (alirocumab) Injection met its primary endpoint ...
DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
Dear Dr. Roach: I am a 66-year-old male diagnosed about 15 years ago with mild coronary artery disease, with some blockages in my peripheral arteries. I was taking the maximum recommended dosage of ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 66-year-old male diagnosed about 15 years ago with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback